Zobrazeno 1 - 8 of 8 pro vyhledávání: '"J. J. Mahany"'
1
A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors
Autor: B. M. Sherman, N. Lewis, Monica M. Mita, J. Rodon, Patricia LoRusso, C. R. Bradley, Anthony W. Tolcher, J. J. Mahany, Elisabeth I. Heath, Kyri Papadopoulos
Publikováno v: Journal of Clinical Oncology. 26:3579-3579
3579 Background: BSI-201 is a small molecule believed to achieve its anti-neoplastic effect by covalently binding and inhibiting PARP-1, and thus expected to potentiate the damage induced by chemot...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae9c392e6685885807449c6cd106cccd
https://doi.org/10.1200/jco.2008.26.15_suppl.3579
Zobrazit plný text záznamu
2
A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung
Autor: Monica M. Mita, K. K. Sankhala, K. Mettinger, John Sarantopoulos, George M. Gill, T. Carmona, Scott A. Soefje, Alain C. Mita, Matthew C. Coffey, J. J. Mahany
Publikováno v: Journal of Clinical Oncology. 26:10568-10568
10568 Background: Reolysin (reovirus serotype 3) is a Dearing strain, naturally occurring, ubiquitous, non-enveloped human reovirus. The community-acquired infection is mild and limited to the uppe...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f1ddc692f08bfd577fce3fbf5c55035d
https://doi.org/10.1200/jco.2008.26.15_suppl.10568
Zobrazit plný text záznamu
3
Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study
Autor: Lionel D. Lewis, Kyriakos P. Papadopoulos, Pamela Bartels, Amanda Seiz, Anthony W. Tolcher, Alain C. Mita, Scott Antonio, E. Till, Anne Keating, Nandi J. Reddy, J. J. Mahany
Publikováno v: Blood. 110:3422-3422
Background: YM155 is a member of a novel class of compounds called survivin suppressants that target survivin. Survivin is a member of the inhibitor of apoptosis proteins (IAPs) family which is responsible for preservation of cell viability and regul
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1099c2eb0ecbd913d1a7c478215fee8
https://doi.org/10.1182/blood.v110.11.3422.3422
Zobrazit plný text záznamu
4
Docetaxel and gefitinib in the first-line treatment of elderly patients (≥70) with advanced non-small cell lung cancer (ANSCLC): Results of phase II trial
Autor: Charles C. Williams, J. J. Mahany, T. Galloway, Alberto Chiappori, S.J. Antonia, Eric B. Haura, George R. Simon, Gerold Bepler
Publikováno v: Journal of Clinical Oncology. 23:7155-7155
7155 Background: Doublet chemotherapy with 2 cytotoxic drugs is considered standard therapy for ANSCLC. We report here the preliminary data from an on going phase II trial combining docetaxel and g...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9fcef6ecdb775a16c5e2c60c25cd019c
https://doi.org/10.1200/jco.2005.23.16_suppl.7155
Zobrazit plný text záznamu
5
Phase I trial of the histone deacetylase inhibitor, valproic acid and the topoisomerase II inhibitor, epirubicin: A clinical and translational Study
Autor: J. J. Mahany, Adil Daud, C. Beam, Daniel M. Sullivan, P. Sullivan, P. N. Munster, Douglas C. Marchion, Elona Bicaku, Richard Lush
Publikováno v: Journal of Clinical Oncology. 23:3084-3084
3084 Background: Pre-clinical data show that histone deacetylase inhibitors(HDACi) potentiate the DNA damage induced by topoisomerase II inhibitors (topo II). Exposure to HDACi results in histone h...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9faed8b8a5c496f822e4595e53454294
https://doi.org/10.1200/jco.2005.23.16_suppl.3084
Zobrazit plný text záznamu
7
Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors
Autor: George R. Simon, Richard Lush, Daniel M. Sullivan, J. J. Mahany, Leticia Tetteh, L. Kvols, Alberto Chiappori
Publikováno v: Journal of Clinical Oncology. 22:2132-2132
2132 Background. Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity. Synergism has been demonstrated between a platinum compound and a top I inhibitor. Addi...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e195b6e05f47a8931c0fa8647c88f51
https://doi.org/10.1200/jco.2004.22.90140.2132
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje